Tegileridine Combined With Intercostal Nerve Block After Thoracoscopic Lung Resection
Study on the Analgesic Effect of Tegileridine Combined With Intercostal Nerve Block After Thoracoscopic Lung Resection
Tongji Hospital
118 participants
Mar 18, 2026
INTERVENTIONAL
Conditions
Summary
Combining tegileridine PCIA with ICNB targeting peripheral nerves, may constitute an ideal analgesic model with complementary advantages. Thus potentially achieving the analgesic goal of "early pain relief, stable throughout the process, and rapid recovery," and may have a positive impact on reducing CPSP.
Eligibility
Inclusion Criteria5
- Age range: 18 to 75 years old;
- Patients undergoing elective thoracoscopic lobectomy or segmentectomy;
- ASA classification levels I-III;
- BMI 18 ~ 30 kg/m2。
- Voluntarily participate and sign an informed consent form.
Exclusion Criteria6
- Patients with preoperative alcohol dependence and long-term use of analgesic drugs are receiving analgesic treatment for other acute and chronic pain;
- Pregnant or lactating women;
- Allergies or other contraindications to the anesthetics, analgesics, and antiemetic drugs used in the study;
- Patients with severe sleep apnea syndrome or acute or severe bronchial asthma;
- Suffering from mental and neurological disorders or cognitive impairment, known or suspected gastrointestinal obstruction, severe liver and kidney dysfunction (Child Pugh score C), chronic obstructive pulmonary disease or severe cardiovascular disease, etc;
- Researchers consider participants who are not suitable to participate in this study and those who refuse to participate.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Administer 0.015 mg/kg (maximum 1mg) of tegileridine intravenously 40 minutes before the end of surgery, followed by the connection of a tegileridine patient-controlled intravenous analgesia (PCIA)
Before closing the chest, the thoracic surgeon injected 3mL of 0.4% ropivacaine into the 4th, 5th, 6th and 7th intercostal spaces through thoracoscopy for intercostal nerve block.
Administer 0.15 μg/kg (maximum 10 μg) of sufentanil intravenously 40 minutes before the end of surgery, followed by the connection of a sufentanil patient-controlled intravenous analgesia (PCIA)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07386626